AR112188A1 - ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS - Google Patents
ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMSInfo
- Publication number
- AR112188A1 AR112188A1 ARP180101347A AR112188A1 AR 112188 A1 AR112188 A1 AR 112188A1 AR P180101347 A ARP180101347 A AR P180101347A AR 112188 A1 AR112188 A1 AR 112188A1
- Authority
- AR
- Argentina
- Prior art keywords
- papain
- oral composition
- pectin
- prepare
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22002—Papain (3.4.22.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición oral a base de pectina y papaína para disminuir los niveles de IGF-1 libre en plasma de personas que lo necesitan, dicha composición comprende pectina de por lo menos 65% de ácido D-galacturónico y papaína con una actividad proteolítica de por lo menos 6.000 U/mg, en donde la pectina y la papaína tienen una relación en peso efectiva de aproximadamente 250:3, respectivamente, y se encuentran humectadas por medio de al menos dos polioles de C₃₋₆, siendo el pH de la composición del orden de 6 obtenido con el agregado de al menos una alcanolamida de C₂₋₆, y comprendiendo además emulsionantes, conservantes y solventes farmacéuticamente aceptables. Métodos para preparar dicha composición oral en cápsula blanda y en jarabe. Método para disminuir los niveles de IGF-1 libre en plasma de personas que lo necesitan con dicha composición oral; que comprende administrara dichas personas una dosificación comprendiendo al menos aproximadamente 250 mg de pectina y al menos aproximadamente 3 mg de papaína cada por lo menos 12 horas durante al menos 28 días. Uso de pectina y papaína en forma conjunta para preparar dicha composición oral.Oral composition based on pectin and papain to decrease the levels of free IGF-1 in plasma of people who need it, said composition comprises pectin of at least 65% of D-galacturonic acid and papain with a proteolytic activity of at least 6,000 U / mg, where pectin and papain have an effective weight ratio of approximately 250: 3, respectively, and are moistened by means of at least two C pol polyols, the pH of the composition being of the order of 6 obtained with the addition of at least one C₂₋₆ alkanolamide, and also comprising emulsifiers, preservatives and pharmaceutically acceptable solvents. Methods for preparing said soft capsule and syrup oral composition. Method to decrease the levels of free IGF-1 in plasma of people who need it with said oral composition; which comprises administering said persons a dosage comprising at least about 250 mg of pectin and at least about 3 mg of papain every at least 12 hours for at least 28 days. Use of pectin and papain together to prepare said oral composition.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP180101347 AR112188A1 (en) | 2018-05-22 | 2018-05-22 | ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS |
PCT/US2019/031326 WO2019226349A1 (en) | 2018-05-22 | 2019-05-08 | Oral composition of citrus pectin and papain to decrease plasma free igf-1 levels in individuals who need it and methods of preparation in soft capsule and syrup dosage forms |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP180101347 AR112188A1 (en) | 2018-05-22 | 2018-05-22 | ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112188A1 true AR112188A1 (en) | 2019-10-02 |
Family
ID=68382491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101347 AR112188A1 (en) | 2018-05-22 | 2018-05-22 | ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR112188A1 (en) |
WO (1) | WO2019226349A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115212226A (en) * | 2021-04-20 | 2022-10-21 | 涛护集团有限公司 | Application of pectin in preparing health product/medicine for improving/reversing chronic kidney disease caused by virus or medicine damage |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916541B2 (en) * | 2011-01-05 | 2014-12-23 | Better Health Publishing, Inc. | Synergistic combination of honokiol and modified citrus pectin in cancer therapy |
US8333961B2 (en) * | 2007-07-03 | 2012-12-18 | Privitera James R | Natural liniment for treatment of skin cancers |
AR102008A1 (en) * | 2015-09-24 | 2017-01-25 | Brix S R L | ACTIVE PHARMACEUTICAL INGREDIENT (IFA) OLEOUS FOR THE TREATMENT OF SKIN AFFECTIONS, COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE THEM |
WO2017184851A1 (en) * | 2016-04-20 | 2017-10-26 | La Jolla Pharmaceutical Company | Compositions and methods for treating cancer |
-
2018
- 2018-05-22 AR ARP180101347 patent/AR112188A1/en unknown
-
2019
- 2019-05-08 WO PCT/US2019/031326 patent/WO2019226349A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019226349A1 (en) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
WO2016004093A3 (en) | Therapeutic compositions including galectin-3 inhibitors and uses thereof | |
CO2019000938A2 (en) | Nmda spiro-lactam modulators and methods of use thereof | |
CO2020009670A2 (en) | Compositions comprising the co-selected microbiota and methods for their use | |
CO2019000945A2 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
CO2019000943A2 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
EA200601761A1 (en) | COMPOSITIONS AS ADJUVANTS FOR STRENGTHENING IMMUNE RESPONSES TO VACCINES AND METHODS OF THEIR USE | |
CO2019000944A2 (en) | Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof | |
CO2019000941A2 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
WO2015183995A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
EA202191079A1 (en) | METHODS FOR TREATMENT OF RETTA SYNDROME WITH FENFLURAMINE | |
CL2019003441A1 (en) | Mic-1 posts and uses of these. | |
AR112166A1 (en) | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B | |
EE200200565A (en) | Combination therapy with vascular adverse effects | |
AR112188A1 (en) | ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS | |
DK1091733T3 (en) | (-) - Pseudoephedrine as a sympathomimetic drug | |
MX2022006940A (en) | Pharmaceutical compositions comprising cabotegravir. | |
WO2015183985A3 (en) | Therapeutic compositions including naphthoquinones and uses thereof | |
WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
DOP2022000004A (en) | PHARMACEUTICAL COMPOSITIONS RESISTANT TO THE DISCHARGE OF DOSES THAT INCLUDE VENIRUNAD | |
AR046665A1 (en) | ORAL FORMULATIONS OF DEOXIPEGANINE AND ITS USES | |
MX2022008036A (en) | New use of bcg immunogenic formulation expressing a respiratory syncitial virus protein against hmpv. | |
AR120399A1 (en) | A METHOD OF TREATMENT OF A DLL3 POSITIVE CANCER | |
AR108792A1 (en) | COMPOSITIONS THAT INCLUDE TIMOLOL | |
AR119669A1 (en) | USE OF INHALED NITRIC OXIDE (iNO) TO IMPROVE ACTIVITY LEVELS IN PATIENTS WITH LUNG DISORDERS |